Stock 002907 CHONGQING PHARSCIN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Chongqing Pharscin Pharmaceutical Co., Ltd. Stock

Equities

002907

CNE100003308

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 18:00:00 2024-04-25 EDT 		5-day change 1st Jan Change
13.31 CNY -0.30% Intraday chart for Chongqing Pharscin Pharmaceutical Co., Ltd. +3.98% -13.85%
04-10 Chongqing Pharscin Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023 CI
04-03 Pharscin Pharma Gets License to Produce Olmesartan Medoxomil Amlodipine Tablets MT

Financials

Sales 2021 846M 117M 159M Sales 2022 785M 108M 148M Capitalization 8.5B 1.17B 1.6B
Net income 2021 91M 12.56M 17.14M Net income 2022 98M 13.53M 18.46M EV / Sales 2021 8.26 x
Net cash position 2021 259M 35.81M 48.88M Net cash position 2022 503M 69.47M 94.83M EV / Sales 2022 10.2 x
P/E ratio 2021
78.9 x
P/E ratio 2022
83.4 x
Employees 1,416
Yield 2021
0.28%
Yield 2022
0.34%
Free-Float 9.66%
More Fundamentals * Assessed data

Chart Chongqing Pharscin Pharmaceutical Co., Ltd.

Dynamic Chart

Latest news about Chongqing Pharscin Pharmaceutical Co., Ltd.

Chongqing Pharscin Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023 CI
Pharscin Pharma Gets License to Produce Olmesartan Medoxomil Amlodipine Tablets MT
Pharscin Pharmaceutical Amends Colon Cleanser Drug's Validity Period MT
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Pharscin Pharmaceutical Gets FDA Nod on Buspirone Hydrochloride Tablets MT
Chongqing Pharscin Pharmaceutical Co., Ltd.(XSEC:002907) added to S&P Global BMI Index CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Pharscin Pharmaceutical Gets Nod to Amend Usage of Bawei Qilong Granules MT
Pharscin Pharma's Production Base Passes US FDA Inspection MT
Pharscin Pharma Gets Approval for Supplementary Application of Traditional Chinese Medicine MT
Chongqing Pharscin Pharmaceutical Co., Ltd. Implements Final Cash Dividend of A shares for 2022, Payable on June 13, 2023 CI
Chongqing Pharscin Pharmaceutical Co., Ltd Approves the Cash Dividend for 2022 CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Pharscin Pharma Obtains China Marketing Rights to Hypertension Drug; Shares Drop 4% MT
Pharscin Pharma’s Profit Rises 3.5% in 2022 Despite 7% Drop in Revenue MT
More news

Analyst Recommendations on Chongqing Pharscin Pharmaceutical Co., Ltd.

Chengxin Rating Terminates Pharscin Pharma’s Credit Ratings After Bond Redemption MT
More recommendations

Quotes and Performance

1 day-0.30%
1 week+3.98%
Current month-5.06%
1 month-4.86%
3 months-8.71%
6 months-19.24%
Current year-13.85%
More quotes

Highs and lows

1 week
12.71
Extreme 12.71
14.03
1 month
12.21
Extreme 12.21
14.51
Current year
9.82
Extreme 9.82
17.43
1 year
9.82
Extreme 9.82
20.50
3 years
9.82
Extreme 9.82
34.85
5 years
9.82
Extreme 9.82
34.85
10 years
5.98
Extreme 5.98
47.92
More quotes

Managers and Directors - Chongqing Pharscin Pharmaceutical Co., Ltd.

Managers TitleAgeSince
Xiao Ying Liu CEO
 Chief Executive Officer 61 15-08-18
Kai Yu Xu CHM
 Chairman 58 00-09-30
Xiao Yan Peng DFI
 Director of Finance/CFO 50 02-02-28
Members of the board TitleAgeSince
Jia Ming Li BRD
 Director/Board Member 58 22-05-17
Hong Tao You CHM
 Chairman 61 15-08-18
Xiao Ying Liu CEO
 Chief Executive Officer 61 15-08-18
More insiders

Quotes

Date Price Change Volume
24-04-26 13.31 -0.30% 2,814,736
24-04-25 13.35 +0.68% 3,522,891
24-04-24 13.26 +1.14% 1,578,711
24-04-23 13.11 +2.10% 2,247,120
24-04-22 12.84 +0.31% 1,651,301

End-of-day quote Shenzhen S.E., April 25, 2024

More quotes

Company Profile

Chongqing Pharscin Pharmaceutical Co Ltd is a China-based company principally engaged in the research, development, production and sale of Chinese patent drugs and chemical drugs. The Company operates three segments: Pharmaceutical Industry segment, Commercial Circulation segment and Retail segment. The Company's products are categorized into the pharmaceuticals of digestive system, nervous system, otorhinolaryngology, cardiovascular and cerebrovascular systems and immune systems. The Company’s products include Weidimei (aluminum carbonate tablets), Ganju Bingmei Tablets, Bawei Qilong Particles, Liuwei Anshen Capsules, Sodium Ferulate for Injection, Omeprazole Sodium for Injection and Gabexate Mesilate for Injection. The Company mainly distributes its products in domestic market.
Sector
Pharmaceuticals
Calendar
2024-04-28 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

1st Jan change Capi.
CHONGQING PHARSCIN PHARMACEUTICAL CO., LTD. Stock Chongqing Pharscin Pharmaceutical Co., Ltd.
-13.85% 767M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+21.10% 43.34B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.44% 21.96B
SANDOZ GROUP AG Stock Sandoz Group AG
+10.86% 14.09B
CIPLA LIMITED Stock Cipla Limited
+12.33% 13.64B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+40.16% 11.43B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.59% 6.86B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+8.46% 5.22B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002907 Stock